Introduction: Who Should Undergo Diagnostics
Neovascular age-related macular degeneration, also known as wet AMD or advanced neovascular AMD, represents a serious form of eye disease that requires careful monitoring and early detection. Determining who should undergo diagnostic testing begins with understanding the risk factors and recognizing when vision changes warrant immediate medical attention.
People over the age of 60 should be particularly vigilant, as age represents the strongest risk factor for developing this condition. The disease is most common among Europeans compared to African, Hispanic, and Asian populations, though it can affect individuals of any background. If you have a family history of macular degeneration, your risk increases significantly, making regular diagnostic screening even more important.[1][2]
Other factors that increase the likelihood of needing diagnostic evaluation include smoking, which increases risk by two to five times, having high cholesterol or high blood pressure, obesity, and being female. People with light-colored irises and those with a lower dietary intake of fish and leafy green vegetables also face elevated risk. Caucasian individuals and those with cardiovascular disease should consider more frequent eye examinations.[4][6]
It’s crucial to seek diagnostic testing immediately if you notice specific vision changes. Straight lines that suddenly appear bent, wavy, or crooked represent a significant warning sign for late-stage AMD. Other symptoms requiring urgent evaluation include the appearance of dark, blurry areas or blank spots in your central vision, or words that seem to disappear while reading. Some people also notice that colors appear less bright than before, or they experience increased difficulty seeing in low lighting conditions.[4][14]
Even if you don’t have symptoms, regular diagnostic screening becomes advisable as you age, particularly after age 55. The condition can progress rapidly once it reaches the neovascular stage, making early detection essential for preserving vision. People who have already been diagnosed with dry AMD in one or both eyes require ongoing monitoring, as this condition can transform into the wet form at any stage.[6][14]
Classic Diagnostic Methods
Diagnosing neovascular age-related macular degeneration involves several specialized techniques that help eye care professionals examine the retina and identify abnormal blood vessel growth. These methods work together to provide a comprehensive picture of what’s happening inside your eye and distinguish wet AMD from other eye conditions.
The foundation of any AMD diagnosis begins with a clinical examination using a slit lamp, which is a specialized microscope that allows your doctor to examine the structures at the back of your eye in detail. During this examination, your pupils will be dilated using special eye drops, which temporarily makes them larger so the doctor can see the retina and macula more clearly. This dilated eye exam remains essential because early AMD shows no symptoms, yet a trained specialist can identify characteristic changes in the retina during this examination.[4][14]
Fluorescein angiography represents one of the most established imaging techniques for diagnosing wet AMD. In this procedure, a special dye called fluorescein is injected into a vein in your arm. As the dye travels through your bloodstream and reaches the blood vessels in your eye, a camera takes rapid photographs. These images reveal the pattern of blood flow and can clearly show where abnormal blood vessels are leaking fluid or blood. The test helps doctors identify the presence, location, and extent of macular neovascular membranes (also called choroidal neovascularization), which are the abnormal blood vessels that define wet AMD.[4]
A similar but complementary technique called indocyanine green angiography uses a different type of dye that can penetrate deeper layers of tissue. This test provides additional information about blood vessels located beneath the retina and can be particularly useful when fluorescein angiography results are unclear or when doctors need more detailed information about the blood vessel patterns.[4]
Optical coherence tomography, commonly abbreviated as OCT, has revolutionized the diagnosis and monitoring of wet AMD. This non-invasive imaging technique uses light waves to create cross-sectional images of your retina, similar to how ultrasound uses sound waves. OCT produces detailed pictures showing the different layers of the retina and can detect even small amounts of fluid accumulation or thickening of the macula. The test takes only minutes and doesn’t require any injections or contact with your eye beyond looking into the machine. All clinical practice guidelines recommend OCT for initial diagnosis of neovascular AMD.[4][12]
A newer advancement called optical coherence tomography angiography (OCTA) combines the detailed imaging of OCT with the ability to visualize blood flow without requiring dye injection. This technology can show the three-dimensional structure of abnormal blood vessels and has become increasingly useful in both diagnosis and treatment monitoring.[4]
Visual acuity testing measures how well you can see at various distances. While it may seem simple, this test provides important baseline information about your vision and helps doctors track changes over time. The test typically involves reading letters on a chart (often called a Snellen chart) from a specific distance. However, visual acuity alone cannot diagnose wet AMD, as vision may remain relatively good in early stages despite the presence of disease.[12]
An Amsler grid test offers a straightforward way to detect vision distortion characteristic of wet AMD. The grid looks like graph paper with a dot in the center. When you look at the dot with one eye at a time, wavy or missing lines on the grid can indicate problems with your macula. Doctors often give patients an Amsler grid to use at home for daily self-monitoring, as sudden changes in how the grid appears can signal disease progression requiring immediate medical attention.[20]
When diagnosing wet AMD, doctors must distinguish it from other conditions that can affect the macula. The combination of clinical examination findings, the pattern of abnormal blood vessels seen on angiography, and the characteristic fluid accumulation visible on OCT scans helps differentiate neovascular AMD from conditions like diabetic retinopathy, retinal vein occlusion, or other forms of macular disease. The presence of specific features like sub-retinal fluid, intra-retinal fluid, or pigment epithelial detachment on OCT imaging, combined with evidence of neovascularization on angiography, confirms the diagnosis of wet AMD.[4][9]
Diagnostics for Clinical Trial Qualification
Clinical trials investigating new treatments for neovascular age-related macular degeneration employ specific diagnostic criteria to identify suitable participants and measure treatment outcomes. Understanding these requirements helps explain the rigorous standards researchers use to evaluate whether experimental therapies work effectively.
Most clinical trials for wet AMD require comprehensive baseline testing to establish the extent of disease before treatment begins. Optical coherence tomography serves as a standard measurement tool in virtually all contemporary studies because it provides objective, quantifiable data about retinal thickness and fluid accumulation. Researchers use OCT scans to measure changes in central retinal thickness and to identify the presence of sub-retinal fluid, intra-retinal fluid, or sub-retinal pigment epithelium fluid. These measurements create a baseline against which treatment effects can be compared over time.[11][12]
Visual acuity testing represents another standard criterion for clinical trial enrollment and outcome measurement. Trials typically specify minimum and maximum visual acuity levels for participation. For example, many studies require that participants have vision that falls within a certain range—not so good that treatment effects would be difficult to measure, but not so poor that significant improvement becomes unlikely. Visual acuity is measured using standardized charts and testing conditions to ensure consistency across different trial sites and time points.[11][12]
Fluorescein angiography and indocyanine green angiography continue to play important roles in clinical trial diagnostics, particularly for confirming the presence and characterizing the type of neovascular lesions. These tests help researchers document the anatomical features of abnormal blood vessels and track changes in leakage patterns during treatment. Some trials require specific characteristics of neovascularization to be present for a patient to qualify for enrollment.[4]
Clinical trial protocols often specify timing and frequency of diagnostic testing. Initial screening may involve multiple imaging sessions to thoroughly characterize each participant’s condition. During the treatment phase, regular monitoring with OCT typically occurs at each visit, which might be monthly or at other specified intervals depending on the study design. Visual acuity testing similarly follows a standardized schedule to track changes in vision over the course of the trial.[11]
Some clinical trials investigating novel therapeutic approaches may require additional specialized diagnostic procedures beyond standard clinical practice. For instance, studies examining gene therapies or new drug delivery systems might include more frequent or more detailed imaging to assess safety and monitor for unexpected effects. Researchers may also collect additional measurements like retinal blood flow, detailed mapping of lesion characteristics, or assessments of reading ability and quality of life to provide comprehensive information about treatment effects.[1][9]
Clinical trials also use standardized criteria for determining when to adjust treatment based on diagnostic findings. For studies of anti-VEGF therapies, protocols specify what OCT or visual acuity changes trigger additional injections or treatment modifications. These “retreatment criteria” ensure consistency in how treatment decisions are made across all trial participants and sites. Common retreatment criteria include loss of visual acuity accompanied by signs of disease activity on OCT, increase in central retinal thickness, new or persistent fluid, or new hemorrhage.[11]
Eligibility criteria for clinical trials may exclude patients with certain diagnostic findings. For example, trials might not accept participants with extensive scarring visible on imaging, very large lesions, or certain types of neovascular membranes that previous research suggests respond poorly to treatment. These exclusion criteria help researchers study more homogeneous patient populations and interpret results more clearly, though they also mean that trial results may not apply to all patients with wet AMD.[9]
